| ||Audit Committee||Compensation Committee||Nominating and Corporate Governance Committee||Science and Technology Committee|
|Burt Adelman, M.D. |
|Burt Adelman, M.D.|
Burt Adelman, M.D., has served as a member of our board of directors since April 2016. Dr. Adelman was Executive Vice President, Research and Development and Chief Medical Officer of Dyax Corp., or Dyax, a biotechnology company, from February 2012 until its acquisition by Shire Plc in January 2016. Prior to joining Dyax, he worked at Eleven Biotherapeutics, Inc., a biotechnology company, where he served as interim President of Research and Development from 2009 to 2010 and as Senior Advisor from...
| || || ||
|Kenneth Bate |
Kenneth Bate has served as a member of our board of directors since January 2014 and as Co-Chairman since February 2016. Mr. Bate is currently an independent consultant. From May 2009 until January 2012, Mr. Bate was the President and Chief Executive Officer of Archemix, a privately held biotechnology company. From January 2007 to April 2009, Mr. Bate was President and Chief Executive Officer of NitroMed, a public pharmaceutical company. From March 2006 until January 2007, Mr. Bate was Chief Ope...
|| || |
|Nicholas Galakatos, Ph.D. |
|Nicholas Galakatos, Ph.D.|
Co-founder and Managing Director, Clarus Ventures
Nicholas Galakatos, Ph.D., has served as a member of our board of directors and chair of the compensation committee since February 2012. Dr. Galakatos is a co-founder of Clarus Ventures, a health care and life science venture capital firm, where he has served as Managing Director since its inception in 2005. Dr. Galakatos has also served as a General Partner of MPM Asset Management II LLC since 2000 and as a General Partner of BioVentures III GP, LP since 2002. From 1997 to 2000, Dr. Galakatos s...
|Jean George |
|Jean George |
General Partner, Advanced Technology Ventures
Jean George has served as a member of our board of directors since October 2013. Since February 2002, she has been a Managing Director at Advanced Technology Ventures, a venture capital fund, where she currently serves as the East Coast lead partner for healthcare investments. Since March 2012, Ms. George has served as Managing Director at LSV Capital Management, a venture capital firm. Ms. George currently serves as a member of the board of directors of the public companies Acceleron Pharma and...
| || ||
Michael Kishbauch has served as a member of our board of directors since April 2016. He has served as a director of Achillion Pharmaceuticals, Inc., or Achillion, a biotechnology company, since July 2004. Mr. Kisbauch has also served as a director of Progenics Pharmaceuticals, Inc., a biopharmaceutical company, since September 2013 and of TetraLogic Pharmaceuticals Corporation, a biopharmaceutical company, since November 2014. Mr. Kishbauch previously served as President and Chief Executive Offi...
|| || || |
|Michael Ross, Ph.D. |
|Michael Ross, Ph.D.|
Managing Partner, SV Life Sciences
Michael Ross, Ph.D., has served as a member of our board of directors since April 2010, as Chairman since October 2010 and as Co-Chairman since February 2016. Since 2002, Dr. Ross has served as a Managing Partner at SV Life Sciences Advisers, LLC, a venture capital firm that he joined as a venture partner in 2001. Previously, Dr. Ross served as the Chief Executive Officer of CyThera, Carta Proteomics, MetaXen and Arris Pharmaceutical. Earlier in his career, Dr. Ross was employed at Genentech, se...